The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...
A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...
Hosted on MSN4d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback